Endometrial Cancer, Endometrial Cancer Stage, Ovarian Cancer, Ovarian Cancer Stage 3, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Ovarian Carcinoma
Conditions
Keywords
Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3, Endometrial Cancer, Aerobic Exercise, Strength Training, Cardiovascular training
Brief summary
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
Detailed description
This research study is a randomized controlled trial that will compare an exercise group to a control group on lower extremity function, CIPN, and inflammatory markers in ovarian or endometrial cancer patients undergoing first-line chemotherapy after surgery. The names of the study interventions involved in this study are/is: * Aerobic and resistance exercise; virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom * Attention control for 16 weeks, home-based stretching The research study procedures include: screening for eligibility and study interventions including evaluations and follow up visits. It is expected that about 30 people will take part in this research study.
Interventions
OTHERExercise
16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
OTHERAttention Control
Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
Sponsors
Dana-Farber Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed patients with stages III-IV ovarian or endometrial cancer * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * Physician's clearance to participate in moderate-vigorous intensity exercise * Able to read, write, and understand English * Ability to understand and the willingness to sign an informed consent document * Willing to undergo two venous blood draws for the study
Exclusion criteria
* Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist * Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist * Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients completing the exercise intervention sessions. | 16 Weeks | The feasibility of the 16-week exercise intervention is defined as the proportion of patients completing the exercise intervention sessions. The analysis population will be the eligible patients who are assigned to the intervention group (N=20). The investigators will estimate the proportion and corresponding 95% exact confidence interval (CI).99 The Investigators expect that the proportion is 70% or higher |
| Enrollment Rate | 16 Weeks | The enrollment rate is defined as the proportion of patients who participate in the study among those patients who are approached for the enrollment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Short Physical Performance Battery (SPPB)-Lower Extremity Function | 16 Weeks | Short Physical Performance Battery (SPPB), an objective measure of lower-extremity function based on three timed tests of standing balance, walking speed, and chair stand tests, which in older adults is predictive of disability, nursing home admission, and all-cause mortality |
| Change in 6-minute walk distance | 16 weeks | Aerobic fitness will be assessed by the 6-minute walk test (6MWT). The 6MWT has been administered in cancer survivors and has a reliability coefficient of 0.93 when tested in cancer survivors. Participants will be instructed to walk as quickly as possible without running on an indoor pre-measured walkway for 6 minutes |
| PROMIS- Physical function | 16 Weeks | Physical function will be assessed using the Patient Reported Outcome Measure Information System (PROMIS) Physical Function-10 scale. |
| Number of Participants with Treatment Related Adverse Events | 16 Weeks | NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. |
Countries
United States
Contacts
CONTACTChristina Dieli-Conwright, PhD
PRINCIPAL_INVESTIGATORChristina Dieli-Conwright, PhD
Dana-Farber Cancer Institute
Outcome results
None listed